Order Article Reprints

Sato Y, Nakano K, Wang X, Fukuda N, Urasaki T, Ohmoto A, Hayashi N, Yunokawa M, Ono M, Tomomatsu J, et al. Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers. 2021; 13(24):6266. https://doi.org/10.3390/cancers13246266

Sato, Yasuyoshi, Kenji Nakano, Xiaofei Wang, Naoki Fukuda, Tetsuya Urasaki, Akihiro Ohmoto, Naomi Hayashi, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, and et al. 2021. "Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma" Cancers 13, no. 24: 6266. https://doi.org/10.3390/cancers13246266

Sato, Y., Nakano, K., Wang, X., Fukuda, N., Urasaki, T., Ohmoto, A., Hayashi, N., Yunokawa, M., Ono, M., Tomomatsu, J., Saito, M., Minami, Y., Hayakawa, K., Funauchi, Y., Tanizawa, T., Ae, K., Matsumoto, S., & Takahashi, S. (2021). Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers, 13(24), 6266. https://doi.org/10.3390/cancers13246266